Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
28 February 2024 - 9:55AM
Business Wire
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics
company, today announced that its Decipher Prostate Genomic
Classifier is the only gene expression test to receive a “Level 1B”
evidence rating in the 2024 NCCN* Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) as a prognostic tool for the risk
stratification of patients with localized prostate cancer. Level 1B
was assigned to Decipher Prostate based on the evidence in both the
post-biopsy and post-prostatectomy settings. Additionally, because
of this classification, the Decipher Prostate test is the only gene
expression test for which the guidelines synthesize the available
published data in a separate table that summarizes treatment
implications for patients based on both their NCCN risk
classification and Decipher score.
“We commend the NCCN panel for their evidence synthesis and
expert consensus that has again designated the Decipher Prostate
test as the gene expression tool for risk stratification supported
by the most clinical evidence across the spectrum of the disease
and has uniquely provided clinical guidance that integrates a
patient’s Decipher score,” said Elai Davicioni, Ph.D., medical
director of Urology for Veracyte. “These recommendations reflect
the extensive clinical evidence generated in collaboration with
clinical trial groups from around the world from analysis of many
thousands of their patients, including those from practice-changing
phase 3 studies. Ultimately, we believe that these guidelines will
help our customers better use the Decipher Prostate test and tumor
biology to provide optimal care for more of their patients with
prostate cancer.”
The new NCCN Guidelines classify the Decipher Prostate test as
Level 1B according to the “Simon Criteria,” which are published
criteria for assigning a level of evidence for clinical biomarkers
based on the quality and quantity of evidence available. They
summarize the treatment implications for patients based on their
Decipher score and the published evidence from analyses of multiple
randomized, phase 3 clinical trials.
About the Decipher Prostate Genomic Classifier
The Decipher Prostate Genomic Classifier is a 22-gene test,
developed using RNA whole-transcriptome analysis and machine
learning, that helps inform treatment decisions for patients with
prostate cancer. The test is performed on biopsy or surgically
resected samples and provides an accurate risk of developing
metastasis with standard treatment. Armed with this information,
the physician can better personalize their patients’ care and may
recommend less-intensive options for those at lower risk or
earlier, more-intensive treatment for those at higher risk of
metastasis. The Decipher Prostate test has been validated in more
than 75 studies involving more than 100,000 patients.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our Veracyte Diagnostics Platform
delivers high-performing cancer tests that are fueled by broad
genomic and clinical data, deep bioinformatic and AI capabilities,
and a powerful evidence-generation engine, which ultimately drives
durable reimbursement and guideline inclusion for our tests, along
with new insights to support continued innovation and pipeline
development. For more information, please visit www.veracyte.com
and follow the company on X (formerly Twitter) at @veracyte.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to the
potential NCCN Guidelines impact on physician’s better use of the
Decipher prostate test. to our expectations the Decipher prostate
test helps physicians better personalize their patients’ care in
recommending less intensive versus more intensive treatment
options. Forward-looking statements can be identified by words such
as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,”
“should,” “may,” “will,” “enable,” “positioned,” “offers,”
“designed” and similar references to future periods. Actual results
may differ materially from those projected or suggested in any
forward-looking statements. These statements involve risks and
uncertainties, which could cause actual results to differ
materially from our predictions, and include, but are not limited
to the impact we believe these guidelines will have in helping our
customers better use the Decipher Prostate test and tumor biology
to provide optimal care for more of their patients with prostate
cancer. Additional factors that may impact these forward-looking
statements can be found under the caption “Risk Factors” in our
Annual Report on Form 10-K filed on March 1, 2023 and our Quarterly
Report on Form 10-Q filed for the three months ended September 30,
2023, filed on November 8, 2023. Copies of these documents, when
available, may be found in the Investors section of our website at
https://investor.veracyte.com. These forward-looking statements
speak only as of the date hereof and, except as required by law, we
specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise. These forward-looking statements speak only as of the
date hereof and, except as required by law, we specifically
disclaim any obligation to update these forward-looking statements
or reasons why actual results might differ, whether as a result of
new information, future events or otherwise.
Veracyte, the Veracyte logo, and Decipher are registered
trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and
selected countries.
* National Comprehensive Cancer Network. NCCN makes no
warranties of any kind whatsoever regarding their content, use or
application and disclaims any responsibility for their application
or use in any way.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227639570/en/
Investors: Shayla Gorman investors@veracyte.com
619-393-1545
Media: Tracy Morris media@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From May 2023 to May 2024